A Study to Evaluate the Safety and Efficacy of CyPep-1 in Combination With Pembrolizumab for the Treatment of Advanced or Metastatic Cancers

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

March 21, 2023

Primary Completion Date

September 23, 2024

Study Completion Date

September 23, 2024

Conditions
Advanced Head and Neck Squamous Cell CarcinomaAdvanced Breast CancerAdvanced Melanoma
Interventions
DRUG

CyPep-1

Intratumoral injection

DRUG

Pembrolizumab 25 MG/ML [KEYTRUDA®]

IV infusion

Trial Locations (25)

35294

University of Alabama at Birmingham, Birmingham

48202

Henry Ford Health System, Detroit

75246

Texas Oncology - Baylor Charles A. Sammons Cancer Center, Dallas

77030

Houston Methodist, Houston

91010

City Of Hope, Duarte

15213-2582

University of Pittsburgh Medical Center, Pittsburgh

Unknown

CHRU de Besançon, Besançon

Institut Bergonie, Bordeaux

CHU Lille, Lille

Centre Leon Berard, Lyon

AP-HM - Hôpital de la Timone, Marseille

Institut Paoli Calmettes, Marseille

Hôpital Saint Louis - AP-HP, Paris

Institute Gustave Roussy, Villejuif

Istituto Europeo di Oncologia, Milan

Azienda Ospedaliero Universitaria Senese, Siena

NKI/AvL, Amsterdam

Maastricht UMC, Maastricht

EMC, Rotterdam

Vall d'Hebron (VHIO), Barcelona

Clinica Universidad de Navarra Madrid, Madrid

Hospital Universitario 12 de Octubre, Madrid

Hospital Universitario HM Sanchinarro, Madrid

Clinica Universidad de Navarra Pamplona, Pamplona

Hospital Universitario Virgen Macarena, Seville

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Cytovation AS

INDUSTRY